Arcturus Therapeutics appoints Dr. Moncef Slaoui to Board of Directors

Arcturus Therapeutics Holdings Inc.

Dr. Moncef Slaoui, former Chief Scientific Advisor for Operation Warp Speed, appointed independent director effective June 19, 2024.
Slaoui brings vaccine industry expertise; previously served on boards of Moderna, Lonza, Vaxcyte, and held leadership at GSK.
Slaoui will receive standard non-employee director compensation as described in 2024 proxy statement.
No arrangements or family relationships with other directors/officers; no reportable transactions under Item 404(a).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Moncef Slaoui

Member of the Board of Directors

ARCT · Arcturus Therapeutics Holdings Inc.

Effective: 2024-06-19
Filed: June 24, 2024, 7:59 PM ET

On June 19, 2024, Dr. Moncef Slaoui, Ph.D., agreed to serve as a member of the Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Moncef Slaoui was appointed as Member of the Board of Directors at Arcturus Therapeutics Holdings Inc..

Action: appointed
Role: Member of the Board of Directors

Exact text from the filing

On June 19, 2024, Dr. Moncef Slaoui, Ph.D., agreed to serve as a member of the Board of Directors

View on SEC.gov

Arcturus Therapeutics Holdings Inc. filing history →

Source: SEC EDGAR

accession 0001193805-24-000842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.